LATEST
CHASING CanFish F2, the World's First 3-In-1 AI Fishing Scout, Officially Launches on KickstarterPatrick Manser and Evan Luthra Break Ground on BANURU Resort & Residences in ZanzibarIDMERIT Named as Highest-Ranked Identity Verification (IDV) Company on the Inc. 5000 List of America's Fastest-Growing Private CompaniesSophie Bert Leads the Islantilla Open After a Day of Fog, Rain and WindGladia Launches Gladia Connect and Gladia Agency‘I Still Love You, Pal’: Biden’s Secret Farewell Praise for Netanyahu Exposes Contradictions Over Gaza WarSPACECOOL Launches “SPACECOOL Heat Shield VT,” Featuring Zero-Energy Radiative Cooling Technology, on Kickstarter “Carry Your Own Tree Shade” — An Innovative Japanese Product Combining Advanced Cooling Technology with Portable Sun ProtectionATMOS Space Cargo and MBDA Deutschland Sign Cooperation Agreement on Precision Orbital Deep Strike (PODS) DevelopmentThe Islantilla Open Officially Opens the LET Access Series Season FinaleKanata and Hanwha Ocean Sign Agreement to Advance Proposed Canadian LNG ProjectCHASING CanFish F2, the World's First 3-In-1 AI Fishing Scout, Officially Launches on KickstarterPatrick Manser and Evan Luthra Break Ground on BANURU Resort & Residences in ZanzibarIDMERIT Named as Highest-Ranked Identity Verification (IDV) Company on the Inc. 5000 List of America's Fastest-Growing Private CompaniesSophie Bert Leads the Islantilla Open After a Day of Fog, Rain and WindGladia Launches Gladia Connect and Gladia Agency‘I Still Love You, Pal’: Biden’s Secret Farewell Praise for Netanyahu Exposes Contradictions Over Gaza WarSPACECOOL Launches “SPACECOOL Heat Shield VT,” Featuring Zero-Energy Radiative Cooling Technology, on Kickstarter “Carry Your Own Tree Shade” — An Innovative Japanese Product Combining Advanced Cooling Technology with Portable Sun ProtectionATMOS Space Cargo and MBDA Deutschland Sign Cooperation Agreement on Precision Orbital Deep Strike (PODS) DevelopmentThe Islantilla Open Officially Opens the LET Access Series Season FinaleKanata and Hanwha Ocean Sign Agreement to Advance Proposed Canadian LNG Project
News

Eveliqure Announces the Initiation of a Phase 1 Clinical Study of Its Combined Shigella and ETEC Vaccine Candidate

Illustration: greatreporter

Eveliqure Biotechnologies GmbH, an Austrian biotechnology company, today announces the initiation of clinical testing for its ShigETEC vaccine candidate, with the dosing of the first subject in a Phase 1 safety and immunogenicity study in Europe.

ShigETEC is an orally administered vaccine candidate targeting Shigella and Enterotoxigenic E. coli (ETEC), two of the major pathogens responsible for diarrhoeal diseases in travelers to endemic countries, as well as a major threat to children living in low- and middle- income countries.

Currently no effective vaccines against these two pathogens exist and previous attempts to develop vaccines against Shigella and ETEC have failed. Eveliqure has employed a radically innovative approach based on a live attenuated Shigella vaccine strain rationally designed to provide broad, serotype independent protection against both Shigella and ETEC, and is developing the vaccine for both travelers to endemic countries and for children living in resource-poor countries.  Following this initial Phase 1 study run in Hungary, further clinical development of ShigETEC  will include Phase 1 testing in non-endemic adults, immune characterization of vaccine responses, vaccine formulation studies and clinical testing of ShigETEC in the pediatric population in resource poor-countries. These activities are supported by the EU-funded SHIGETECVAX international consortium of world-leading vaccine organizations - the European Vaccine Initiative, Eveliqure Biotechnologies, University of Gothenburg, icddr,b and PATH.

“Entering clinical development with ShigETEC marks a major milestone for Eveliqure, culminating from our extensive preclinical work performed over the past five years” - commented Gábor Somogyi, MD, MBA, Chief Executive Officer of Eveliqure. “We believe that ShigETEC has the potential to reduce the burden of diarrhoeal diseases for travellers, while also saving hundreds of thousands of children in endemic areas of the world”.

“Initiating the Phase 1 study for ShigETEC in adult volunteers is a crucial step towards establishing safety and immunogenicity of our vaccine candidate, and will help us define a well-tolerated, and effective schedule of dosing for our planned Phase 2 human challenge studies”. – commented Frank Malinoski MD, PhD, Chief Medical Officer of Eveliqure.

Compared to single pathogen approaches, ShigETEC has the potential to have a major impact on diarrheal diseases, protecting both travelers to the developing world and children in endemic populations.

Eveliqure is an Austrian biotechnology company in Vienna that has developed a proprietary vaccine technology platform aiming at improving the quality of life for both the poor and the privileged by providing innovative medical solutions to fight diarrhoeal diseases. Eveliqure is resident at CEBINA, the Central European Biotech Incubator and Accelerator (www.cebina.eu).

www.eveliqure.com

The SHIGETECVAX project has received funding from the European Union’s Horizon 2020 research and innovation program under grant agreement No 815568.

This project has also received funding from the Wellcome Trust under award number 212399/C/18/Z.

Related articles

Top